Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 14, 2023 at 04:01 pm EDT
Share
Kezar Life Sciences, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 18.18 million compared to USD 14.21 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.25 a year ago. Diluted loss per share from continuing operations was USD 0.25 compared to USD 0.25 a year ago.
For the full year, the company reported net loss was USD 68.24 million compared to USD 54.63 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 1.04 a year ago. Diluted loss per share from continuing operations was USD 1.01 compared to USD 1.04 a year ago.
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.